IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.674 – $0.812
Volume16,740
Market cap$12M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$12.12M
Price / earnings
—
Price / book
3.33×
Price / sales
0.24×
EV / sales
0.22×
EV / EBITDA
-4.82×
Profitability
Earnings per share
-$0.20
Return on assets
-13.01%
Return on equity
-97.47%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.04×
Current ratio
1.82×
Quick ratio
1.08×
Cash ratio
0.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IRIX, quarterly periods
Line item
Q2 FY2026 Jul 4, 2026
Q1 FY2026 Apr 4, 2026
Q4 FY2025 Jan 3, 2026
Q3 FY2025 Sep 27, 2025
Q2 FY2025 Jun 28, 2025
Q1 FY2025 Mar 29, 2025
Q4 FY2024 Dec 28, 2024
Q3 FY2024 Sep 28, 2024
Revenue
$12.57M
$11.8M
$14.72M
$12.48M
$13.57M
$11.9M
$12.7M
$11.58M
Cost of revenue
$8.27M
$7.06M
$9.25M
$8.47M
$8.89M
$6.84M
$7.11M
$7.26M
Gross profit
$4.3M
$4.74M
$5.48M
$4.01M
$4.68M
$5.06M
$5.59M
$4.32M
Selling, general and administrative
$4.39M
$4.16M
$4.54M
$4.45M
$4.75M
$4.38M
$4.98M
$4.89M
Research and development
$936K
$905K
$949K
$972K
$871K
$876K
$1.11M
$1.3M
Total operating expenses
$5.33M
$5.07M
$5.49M
$5.42M
$5.62M
$5.26M
$6.09M
$6.19M
Operating income
-$1.03M
-$324K
-$15K
-$1.41M
-$940K
-$205K
-$502K
-$1.87M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$1.2M
-$466K
-$164K
-$1.57M
-$973K
-$1.67M
-$840K
-$1.92M
Income taxes
$70K
$58K
$20K
$4K
$21K
$12K
-$6K
$17K
Net income
-$1.27M
-$524K
-$184K
-$1.57M
-$994K
-$1.69M
-$834K
-$1.93M
Net income attributable to common shareholders
-$1.27M
-$524K
-$184K
-$1.57M
-$994K
-$1.69M
-$834K
-$1.93M
EBITDA
-$943K
-$224K
$136K
-$1.3M
-$813K
-$70K
-$367K
-$1.73M
Basic earnings per share
-$0.07
-$0.03
-$0.01
-$0.09
-$0.06
-$0.10
-$0.05
-$0.12
Diluted earnings per share
-$0.07
-$0.03
-$0.01
-$0.09
-$0.06
-$0.10
-$0.05
-$0.12
Recent news
Company coverage with links to the original publishers.
Iridex Corporation announced the publication of a two-year clinical study in the International Journal of Ophthalmology demonstrating that MicroPulse transscleral laser therapy (TLT) significantly reduces intraocular pressure and medication burden in patients with early to advanced glaucoma. The study of 84 eyes showed mean IOP reduction from 22.32 mmHg to 14.05 mmHg, with 86% success rate in POAG patients and 81% in PACG patients, with no reported complications or visual acuity reductions.
Iridex Corporation announced its intent to relocate its headquarters from Mountain View, California to San Jose, California. The company signed a non-binding letter of intent for a 31,000 square feet location on January 26, 2026, expecting to generate approximately $0.4 million in savings for fiscal year 2026 and $0.6 million in annualized savings thereafter. The relocation is part of the company's ongoing cost reduction strategy while maintaining operations and talent attraction in the Bay Area.
An independent study demonstrated that retreatment with MicroPulse® transscleral laser technology can safely reduce intraocular pressure in glaucoma patients, with IOP reductions ranging from 25% to 35% across different patient groups.
Medical device company Iridex reported Q2 2025 results with modest revenue growth, narrower net loss, and positive adjusted EBITDA, driven by cost control and operational discipline.
Iridex Corporation, a leader in laser-based medical systems for ophthalmology, commented on recent stock price volatility, stating that there have been no material changes to its operating or financial condition.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.